One-Year Quality of Life Post-Pneumonia Diagnosis in Japanese Adults.
pneumococcal pneumonia
quality of life
quality-adjusted life years
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
15 07 2021
15 07 2021
Historique:
received:
30
10
2018
accepted:
21
05
2020
pubmed:
25
5
2020
medline:
5
8
2021
entrez:
25
5
2020
Statut:
ppublish
Résumé
Pneumonia is a common, serious illness in the elderly, with a poorly characterized long-term impact on health-related quality of life (HRQoL). The Japanese Goto Epidemiology Study is a prospective, active, population-based surveillance study of adults with X-ray/CT scan-confirmed community-onset pneumonia, assessing the HRQoL outcome quality-adjusted life-years (QALYs). We report QALY scores and losses among a subset of participants in this study. QALYs were derived from responses to the Japanese version of the EuroQol-5D-5L health-state classification instrument at days 0, 7, 15, 30, 90, 180, and 365 after pneumonia diagnosis from participants enrolled from June 2017 to May 2018. We used patients as their own controls, calculating comparison QALYs by extrapolating EuroQol-5D-5L scores for day -30, accounting for mortality and changes in scores with age. Of 405 participants, 85% were aged ≥65 years, 58% were male, and 69% were hospitalized for clinically and radiologically confirmed pneumonia. Compliance with interviews by patients or proxies was 100%. Adjusted EuroQol-5D-5L scores were 0.759, 0.561, 0.702, and 0.689 at days -30, 0 (diagnosis), 180, and 365, respectively. Average scores at all time points remained below the average day -30 scores (P ≤ .001). Pneumonia resulted in a 1-year adjusted loss of 0.13 QALYs (~47.5 quality-adjusted days) (P < .001). Substantial QALY losses were observed among Japanese adults following pneumonia diagnosis, and scores had not returned to prediagnosis levels at 1 year postdiagnosis. QALY scores and cumulative losses were comparable to those in US adults with chronic heart failure, stroke, or renal failure.
Sections du résumé
BACKGROUND
Pneumonia is a common, serious illness in the elderly, with a poorly characterized long-term impact on health-related quality of life (HRQoL). The Japanese Goto Epidemiology Study is a prospective, active, population-based surveillance study of adults with X-ray/CT scan-confirmed community-onset pneumonia, assessing the HRQoL outcome quality-adjusted life-years (QALYs). We report QALY scores and losses among a subset of participants in this study.
METHODS
QALYs were derived from responses to the Japanese version of the EuroQol-5D-5L health-state classification instrument at days 0, 7, 15, 30, 90, 180, and 365 after pneumonia diagnosis from participants enrolled from June 2017 to May 2018. We used patients as their own controls, calculating comparison QALYs by extrapolating EuroQol-5D-5L scores for day -30, accounting for mortality and changes in scores with age.
RESULTS
Of 405 participants, 85% were aged ≥65 years, 58% were male, and 69% were hospitalized for clinically and radiologically confirmed pneumonia. Compliance with interviews by patients or proxies was 100%. Adjusted EuroQol-5D-5L scores were 0.759, 0.561, 0.702, and 0.689 at days -30, 0 (diagnosis), 180, and 365, respectively. Average scores at all time points remained below the average day -30 scores (P ≤ .001). Pneumonia resulted in a 1-year adjusted loss of 0.13 QALYs (~47.5 quality-adjusted days) (P < .001).
CONCLUSIONS
Substantial QALY losses were observed among Japanese adults following pneumonia diagnosis, and scores had not returned to prediagnosis levels at 1 year postdiagnosis. QALY scores and cumulative losses were comparable to those in US adults with chronic heart failure, stroke, or renal failure.
Identifiants
pubmed: 32447366
pii: 5843589
doi: 10.1093/cid/ciaa595
pmc: PMC8282327
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
283-290Informations de copyright
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America.
Références
J Clin Epidemiol. 2017 Jan;81:22-32
pubmed: 27622778
Am J Respir Crit Care Med. 2005 Feb 15;171(4):388-416
pubmed: 15699079
Thorax. 2012 Jan;67(1):71-9
pubmed: 20729232
Eur Respir J. 2003 Jan;21(1):135-43
pubmed: 12570122
J Gen Intern Med. 2016 Aug;31(8):901-8
pubmed: 26976292
Lancet. 2015 Jan 10;385(9963):117-71
pubmed: 25530442
JAMA. 2000 Feb 9;283(6):749-55
pubmed: 10683053
Clin Trials. 2017 Jun;14(3):255-263
pubmed: 28545337
Health Econ. 2005 Nov;14(11):1169-89
pubmed: 15942981
J Clin Epidemiol. 2009 Dec;62(12):1323-31
pubmed: 19615856
Qual Life Res. 2016 Mar;25(3):707-19
pubmed: 26303761
N Engl J Med. 2015 Jul 30;373(5):415-27
pubmed: 26172429
J Crit Care. 2015 Aug;30(4):721-6
pubmed: 25818842
JAMA. 2018 Jun 26;319(24):2473-2474
pubmed: 29800152
PLoS One. 2015 Mar 30;10(3):e0122247
pubmed: 25822890
Clin Infect Dis. 2007 Mar 1;44 Suppl 2:S27-72
pubmed: 17278083
Ann Intern Med. 2005 Feb 1;142(3):165-72
pubmed: 15684204
Vaccine. 2020 Feb 11;38(7):1770-1777
pubmed: 31889609
Clin Infect Dis. 2017 Nov 13;65(11):1806-1812
pubmed: 29020164
Chest. 2006 Oct;130(4):1165-72
pubmed: 17035452
BMC Infect Dis. 2017 Mar 14;17(1):208
pubmed: 28292280
Qual Life Res. 1993 Jun;2(3):169-80
pubmed: 8401453
Health Policy. 1996 Jul;37(1):53-72
pubmed: 10158943
Curr Med Res Opin. 2017 Feb;33(2):193-200
pubmed: 27733082
Med Decis Making. 2006 Jul-Aug;26(4):410-20
pubmed: 16855129
JAMA. 1997 Jul 2;278(1):32-9
pubmed: 9207335
Qual Life Res. 2011 Dec;20(10):1727-36
pubmed: 21479777
Pediatrics. 2004 Feb;113(2):283-90
pubmed: 14754939
Med Care. 1992 Jun;30(6):473-83
pubmed: 1593914
J Gen Intern Med. 1997 Jul;12(7):423-30
pubmed: 9229281
Curr Med Res Opin. 2009 Apr;25(4):929-42
pubmed: 19257798
Vaccine. 2011 Apr 18;29(18):3398-412
pubmed: 21397721
Environ Health Prev Med. 2011 Jan;16(1):25-35
pubmed: 21432214